- Home
- LBTYK vs RARE Comparison
LBTYK vs RARE Comparison
Compare LBTYK & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYK | RARE |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | LBTYK | RARE |
|---|---|---|
| Price | $10.86 | $24.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $76.45 |
| AVG Volume (30 Days) | 832.1K | ★ 3.6M |
| Earning Date | 02-18-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,770,600,000.00 | $630,598,000.00 |
| Revenue This Year | $13.82 | $19.09 |
| Revenue Next Year | $1.27 | $20.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 170.50 | 20.63 |
| 52 Week Low | $9.21 | $18.41 |
| 52 Week High | $13.62 | $46.50 |
Technical Indicators
Market Signals| Indicator | LBTYK | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 35.40 |
| Support Level | $10.40 | $22.07 |
| Resistance Level | $11.25 | $24.00 |
| Average True Range (ATR) | 0.25 | 1.47 |
| MACD | -0.02 | -1.02 |
| Stochastic Oscillator | 51.09 | 34.87 |
Price Performance
Historical ComparisonAbout LBTYK Liberty Global Ltd. Class C
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.